Holen Sie sich die Stockscreener-App
60.56
2.02%
1.20
Handel nachbörslich:
60.03
-0.53
-0.88%
Schlusskurs vom Vortag:
$59.36
Offen:
$58.85
24-Stunden-Volumen:
2.05M
Relative Volume:
0.72
Marktkapitalisierung:
$11.47B
Einnahmen:
$2.83B
Nettoeinkommen (Verlust:
$-1.02B
KGV:
-10.99
EPS:
-5.51
Netto-Cashflow:
$194.14M
1W Leistung:
+4.87%
1M Leistung:
+12.27%
6M Leistung:
+36.86%
1J Leistung:
-14.57%
1-Tages-Spanne:
$58.53
$60.97
1-Wochen-Bereich:
$57.75
$60.97
52-Wochen-Spanne:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
60.56 | 11.24B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
525.83 | 198.09B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
206.15 | 146.89B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
636.91 | 50.67B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.04 | 39.19B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
204.76 | 34.64B | 15.70B | 1.24B | 2.01B | 6.9036 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Why Exact Sciences Corporation stock is in analyst buy zoneWeekly Volume Report & AI Driven Price Forecasts - newser.com
Is Exact Sciences Corporation stock a buy in volatile markets2025 Buyback Activity & Expert Approved Trade Ideas - newser.com
How high can Exact Sciences Corporation stock goRate Hike & High Yield Equity Trading Tips - newser.com
Published on: 2025-10-12 23:07:32 - newser.com
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
What’s the recovery path for long term holders of Exact Sciences CorporationNew Guidance & Safe Entry Trade Reports - newser.com
Exact Sciences Corporation $EXAS Shares Sold by Blair William & Co. IL - MarketBeat
Doyle, Exact Sciences director, sells $120k in shares By Investing.com - Investing.com Australia
Herriott James, Exact Sciences SVP, sells $90k in EXAS stock - Investing.com Canada
Insider Sell: James Doyle Sells 2,000 Shares of Exact Sciences C - GuruFocus
Doyle, Exact Sciences director, sells $120k in shares - Investing.com India
Can Exact Sciences Corporation (EXK) stock sustain institutional flowsJuly 2025 Final Week & Daily Profit Focused Stock Screening - newser.com
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock - Yahoo Finance
What analysts say about Exact Sciences Corporation EXK stockFibonacci Extensions & Free Unmatched Market Gains - earlytimes.in
Exact Sciences (EXAS): Taking Stock of Valuation Following Recent Share Price Momentum - Yahoo Finance
Piper Sandler raises Exact Sciences stock price target to $70 on Cologuard growth - Investing.com India
EXAS: Piper Sandler Raises Price Target to $70, Maintains Overwe - GuruFocus
Piper Sandler raises Exact Sciences stock price target to $70 on Cologuard growth By Investing.com - Investing.com South Africa
Exact Sciences Corp.New Study in Journal of the National Cancer Institute Finds Cologuard Plus Provides the Most Life-Years Gained with the Fewest Colonoscopies - MarketScreener
Exact Sciences (NASDAQ:EXAS) Upgraded at Zacks Research - MarketBeat
Exact Sciences Corporation $EXAS Shares Bought by Gagnon Securities LLC - MarketBeat
Press Release: Exact Sciences Schedules Third Quarter 2025 Earnings Call - 富途牛牛
Exact Sciences Schedules Third Quarter 2025 Earnings Call - Business Wire
Exact Sciences Corporation $EXAS Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Evercore ISI Group Raises Price Target for EXAS to $68.00 | EXAS Stock News - GuruFocus
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? - Yahoo Finance
Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Study finds Cologuard Plus efficient for colorectal cancer screening By Investing.com - Investing.com Nigeria
Study finds Cologuard Plus efficient for colorectal cancer screening - Investing.com
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies - Yahoo Finance
Real time pattern detection on Exact Sciences Corporation stockWeekly Profit Analysis & Weekly High Momentum Picks - newser.com
Will Exact Sciences Corporation see short term momentumTrade Ideas & Fast Moving Market Watchlists - newser.com
How Recent Developments Are Reshaping the Story for Exact Sciences - Yahoo Finance
Will Analyst Upgrades and Earnings Revisions Shift Exact Sciences' (EXAS) Investment Narrative? - simplywall.st
Exact Sciences (EXAS): Evaluating Upside Potential as Analyst Optimism and New Catalysts Drive Attention - simplywall.st
Best data tools to analyze Exact Sciences Corporation stockTrade Risk Summary & Technical Pattern Based Signals - newser.com
Will Exact Sciences Corporation (EXK) stock announce special dividendEarnings Beat & Accurate Entry and Exit Point Alerts - newser.com
How sentiment analysis helps forecast Exact Sciences Corporation2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Using economic indicators to assess Exact Sciences Corporation potentialTrade Risk Assessment & Precise Trade Entry Recommendations - newser.com
Will Exact Sciences Corporation stock deliver consistent dividendsWeekly Gains Report & Capital Efficiency Focused Strategies - newser.com
Is Exact Sciences Corporation forming a reversal patternJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
EXAS: Barclays Raises Price Target to $65.00 Amid Overweight Rat - GuruFocus
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock - Yahoo Finance
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Published on: 2025-10-01 06:45:18 - newser.com
Benchmark raises Exact Sciences stock price target to $60 on cancer test launch - Investing.com
Archford Capital Strategies LLC Acquires New Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exact Sciences Corp-Aktie (EXAS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Doyle James Edward | Director |
Oct 09 '25 |
Sale |
60.00 |
2,000 |
120,000 |
57,962 |
0.95%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):